Patents by Inventor Fengbin Song
Fengbin Song has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230110178Abstract: Macrocyclic chelators for chelation of alpha-emitting radiometal ions, such as actinium-225 are provided. Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof. The radioimmunoconjugates can be produced by click chemistry reactions. Methods of using the radiocomplexes and radioimmunoconjugates for selectively targeting neoplastic cells for radiotherapy and for treating neoplastic diseases and disorders are also described.Type: ApplicationFiled: June 30, 2022Publication date: April 13, 2023Inventors: RHYS SALTER, VADIM DUDKIN, FENGBIN SONG, WEI ZHANG, SHALOM GOLDBERG, JOHN KEITH
-
Patent number: 11576986Abstract: Macrocyclic chelators for chelation of alpha-emitting radiometal ions, such as actinium-225 are provided. Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof. The radioimmunoconjugates can be produced by click chemistry reactions. Methods of using the radiocomplexes and radioimmunoconjugates for selectively targeting neoplastic cells for radiotherapy and for treating neoplastic diseases and disorders are also described.Type: GrantFiled: May 8, 2020Date of Patent: February 14, 2023Assignee: JANSSEN BIOTECH, INC.Inventors: Rhys Salter, Vadim Dudkin, Fengbin Song, Wei Zhang, Shalom Goldberg, John Keith
-
Publication number: 20220143231Abstract: The present invention is directed to compounds and pharmaceutically acceptable salts thereof, immunoconjugates, radioimmunoconjugates thereof, pharmaceutical compositions containing said compounds and immunoconjugates, radioimmunoconjugates thereof, and the use of said compounds and immunoconjugates, radioimmunoconjugates thereof, in the treatment of neuroplastic diseases or disorders.Type: ApplicationFiled: November 9, 2021Publication date: May 12, 2022Inventors: Rhys Salter, Vadim Y. Dudkin, Fengbin Song, Wei Zhang, Shalom Goldberg, John Keith
-
Patent number: 11098016Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.Type: GrantFiled: August 12, 2020Date of Patent: August 24, 2021Assignee: JANSSEN PHARMACEUTICA NVInventors: Guozhang Xu, Micheal Gaul, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
-
Publication number: 20200377462Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.Type: ApplicationFiled: August 12, 2020Publication date: December 3, 2020Inventors: Guozhang Xu, Micheal Gaul, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
-
Publication number: 20200353105Abstract: Macrocyclic chelators for chelation of alpha-emitting radiometal ions, such as actinium-225 are provided. Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof. The radioimmunoconjugates can be produced by click chemistry reactions. Methods of using the radiocomplexes and radioimmunoconjugates for selectively targeting neoplastic cells for radiotherapy and for treating neoplastic diseases and disorders are also described.Type: ApplicationFiled: May 8, 2020Publication date: November 12, 2020Inventors: Rhys Salter, Vadim Dudkin, Fengbin Song, Wei Zhang, Shalom Goldberg, John Keith
-
Patent number: 10774048Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.Type: GrantFiled: January 8, 2019Date of Patent: September 15, 2020Assignee: JANSSEN PHARMACEUTICA NVInventors: Guozhang Xu, Micheal Gaul, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
-
Publication number: 20190218186Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.Type: ApplicationFiled: January 8, 2019Publication date: July 18, 2019Inventors: Guozhang Xu, Micheal Gaul, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
-
Patent number: 10214493Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.Type: GrantFiled: September 5, 2017Date of Patent: February 26, 2019Assignee: JANSSEN PHARMACEUTICA NVInventors: Micheal Gaul, Guozhang Xu, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
-
Patent number: 10000473Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.Type: GrantFiled: September 5, 2017Date of Patent: June 19, 2018Assignee: JANSSEN PHARMACEUTICA NVInventors: Micheal Gaul, Guozhang Xu, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
-
Publication number: 20180065955Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.Type: ApplicationFiled: September 5, 2017Publication date: March 8, 2018Inventors: Micheal Gaul, Guozhang Xu, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
-
Publication number: 20180065934Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.Type: ApplicationFiled: September 5, 2017Publication date: March 8, 2018Inventors: Micheal Gaul, Guozhang Xu, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
-
Patent number: 9771375Abstract: The present invention is directed to substituted indazole compounds, pharmaceutical compositions of these compounds and methods of use thereof. The compounds of the present invention are ketohexokinase (KHK) inhibitors, useful for treating or ameliorating a KHK mediated metabolic disorders and/or diseases such as obesity, Type II diabetes mellitus and Metabolic Syndrome X. In some embodiments, the substituted indazole compounds are of formula I, wherein R1-R3, Q, X, Y, Z, a, and b are defined herein.Type: GrantFiled: July 23, 2014Date of Patent: September 26, 2017Assignee: Janssen Pharmaceutica NVInventors: Xuqing Zhang, Marta C Abad, Alan C. Gibbs, Gee-Hong Kuo, Fengbin Song, Zhihua Sui, Lawrence C. Kuo
-
Publication number: 20140336170Abstract: The present invention is directed to substituted indazole compounds, pharmaceutical compositions of these compounds and methods of use thereof. The compounds of the present invention are ketohexokinase (KHK) inhibitors, useful for treating or ameliorating a KHK mediated metabolic disorders and/or diseases such as obesity, Type II diabetes mellitus and Metabolic Syndrome X.Type: ApplicationFiled: July 23, 2014Publication date: November 13, 2014Applicant: JANSSEN PHARMACEUTICA NVInventors: Xuqing Zhang, Marta C. Abad, Alan C. Gibbs, Gee-Hong Kuo, Fengbin Song, Zhihua Sui
-
Patent number: 8822447Abstract: The present invention is directed to substituted indazole compounds of formula (I) pharmaceutical compositions of these compounds and methods of use thereof. The compounds of the present invention are ketohexokinase (KHK) inhibitors, useful for treating or ameliorating a KHK mediated metabolic disorders and/or diseases such as obesity, Type II diabetes mellitus and Metabolic Syndrome X.Type: GrantFiled: April 21, 2011Date of Patent: September 2, 2014Assignee: Janssen Pharmaceutica NVInventors: Xuqing Zhang, Marta C. Abad, Alan C. Gibbs, Gee-Hong Kuo, Lawrence C. Kuo, Fengbin Song, Zhihua Sui
-
Patent number: 8748624Abstract: The present invention is directed to picolanmido-propanoic acid derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.Type: GrantFiled: May 23, 2012Date of Patent: June 10, 2014Assignee: Janssen Pharmaceutica NVInventors: Devraj Chakravarty, Kevin Kreutter, Mark Powell, Brian Shook, Fengbin Song, Guozhang Xu, Shyh-Ming Yang, Rui Zhang, Bao-Ping Zhao
-
Publication number: 20120302610Abstract: The present invention is directed to picolanmido-propanoic acid derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.Type: ApplicationFiled: May 23, 2012Publication date: November 29, 2012Inventors: Devraj Chakravarty, Kevin Kreutter, Mark Powell, Brian Shook, Fengbin Song, Guozhang Xu, Shyh-Ming Yang, Rui Zhang, Bao-Ping Zhao
-
Publication number: 20110263559Abstract: The present invention is directed to substituted indazole compounds, pharmaceutical compositions of these compounds and methods of use thereof. The compounds of the present invention are ketohexokinase (KHK) inhibitors, useful for treating or ameliorating a KHK mediated metabolic disorders and/or diseases such as obesity, Type II diabetes mellitus and Metabolic Syndrome X.Type: ApplicationFiled: April 21, 2011Publication date: October 27, 2011Inventors: Xuqing ZHANG, Marta G. ABAD, Alan C. GIBBS, Gee-Hong KUO, Lawrence C. KUO, Fengbin SONG, Zhihua SUI
-
Patent number: 7750048Abstract: The invention is directed to compounds of Formula (I) useful as GPR40 agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, insulin resistance, hyperglycemia, obesity, diabetes such as NIDDM, and other disorders related to lipid metabolism, energy homeostasis, and complications thereof, using compounds of the invention are also described.Type: GrantFiled: November 13, 2007Date of Patent: July 6, 2010Assignee: Janssen Pharmaceutica NVInventors: Gee-Hong Kuo, Fengbin Song, Joseph Gunnet, Keith Demarest
-
Publication number: 20080176912Abstract: The invention is directed to compounds of Formula (I) useful as GPR40 agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, insulin resistance, hyperglycemia, obesity, diabetes such as NIDDM, and other disorders related to lipid metabolism, energy homeostasis, and complications thereof, using compounds of the invention are also described.Type: ApplicationFiled: November 13, 2007Publication date: July 24, 2008Inventors: Gee-Hong Kuo, Fengbin Song, Joseph Gunnet, Keith Demarest